[HTML][HTML] Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems …
NR Aggarwal, LE Beaty, TD Bennett, LE Fish… - The Lancet Regional … - thelancet.com
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
[HTML][HTML] Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems …
NR Aggarwal, LE Beaty, TD Bennett, LE Fish… - The Lancet Regional …, 2024 - Elsevier
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …